Acute hepatitis (non hepatitis A-E) case report form

Introduction

This is a case report form being used to report cases with unexplained acute hepatitis (non hepatitis A to E). The case definitions, which will evolve based on ongoing investigations, are:

Confirmed: N/A at present

Probable:

A person who is 16 years and younger presenting with severe acute hepatitis since 1
 October 2021 and requiring hospitalization,

AND

With elevated serum transaminase >500 IU/L (AST or ALT),
 AND

 Excluding hepatitis caused or attributed to a hepatitis virus (A, B, C, D, E¹) or a known or expected presentation of a drug or medication; a genetic, congenital, or metabolic condition; an oncologic, vascular, or ischemia related condition; or an acute worsening of chronic hepatitis.

¹If hepatitis D or E serology results are pending or test was not done, but other criteria met, these can be reported as probable cases.

This case report form will require information from both the clinical team and the parent/guardian of the case.

FOR LOCAL USE ONLY - PLEASE REMOVE THIS PAGE IF SENDING TO PHAC				
Case information				
Case name:	Proxy name:			
Personal health identifier:				
Street Address:	Home phone:			
City/Town: Postal Code:	Work phone:			

Public Health Agency of Canada - Acute hepatitis (non hepatitis A-E) case report form

Date reported to (dd/mm/yyyy):	PHAC		Initial re Updated	•	
Section 1: Rep	orter o	details			
Public health aut	hority				
Name:			Title:		
Cell phone:			Email a	ddress:	
Province or Terri	tory:				
Clinician			ı		
Name:			Title:		
Cell phone:			Email a		
Organization:			Date of (dd/mm/	interview ⁄yyyy):	
Section 2: Cas	e infor	mation			
Month and				Female	
Year of birth			Sex:	Male	
(mm/yyyy):				Other	
	□ Bla	ck (e.g. African, Afro-Caribbean, Afr	rican Cana	adian descent)	
	☐ East/Southeast Asian (e.g. Chinese, Korean, Japanese, Taiwanese descent or Filipino, Vietnamese,				
Ethnicity/					
Race* (check all that apply):	☐ Indigenous (e.g. First Nations, Inuk/Inuit, Métis descent)				
an triat apply).	all that apply): ☐ Latino (e.g. Latin American, Hispanic descent) ☐ Middle Eastern (e.g. Arab, Persian, West Asian descent – i.e. Afghan, Egyptian, Iranian, Lebanese,				
Turkish, Kurdish)					
*Indicates the population South Asian (e.g. South Asian descent – i.e. East Indian, Pakistani, Bangladeshi, Sri Lankan, Indo-					
group to which Caribbean)					
the case most White (e.g. European descent)					
closely Other, specify:					
identifies					
☐ Prefer not to answer ☐ Unknown					
		st Nations			
_	f Indigenous,				
indicate which Includes member of a Metis organization or Settlement) Indigenous □ Inuk/Inuit					
identity the		er Indigenous, specify:			
case self- □ Not asked					
identifies as:					
	□ Unł	known			



Section 3: Current case status					
Alive, recovered and discharged					
Alive, discharged and recovering					
Alive, in hospital					
Alive, in intensive care (ICU/CCU)					
Deceased					
Unknown					
More information:					
Name of hospital where diagnos hepatitis	sis of acute was made:	Unknown □			
Was liver transplant required?	Yes ☐ No ☐ Iknown ☐	Name of hospital and date of liver transplant if applicable:	Hospital Unknown □ Date Unknown □		
		,			
Section 4: Presenting illness of case					
Please provide a summary of the symptoof onset if known:	oms and sig	ns of the presenting illness (in	cluding prodromal symptoms) and dates		
Symptom	Symptom	present	Symptom onset date (dd/mm/yyyy)		
Jaundice	Yes 🗆	No 🗆			
Nausea	Yes 🗆	No 🗆			
Abdominal pain/ cramping	Yes □	No 🗆			
Diarrhea	Yes □	No 🗆			
Bloody stool	Yes 🗆	No 🗆			
Pale stool	Yes 🗆	No 🗆			
Dark urine	Yes 🗆	No 🗆			
Rash	Yes 🗆	No 🗆			
Vomiting	Yes 🗆	No 🗆			
Respiratory Symptoms – shortness of breath, cough	Yes 🗆	No 🗆			
Upper Respiratory Symptoms – runny nose, congestion, sore throat	Yes 🗆	No 🗆			
Fever	Yes 🗆	No 🗆			
Malaise/ tiredness	Yes 🗆	No 🗆			
Conjunctivitis	Yes 🗆	No 🗆			
Other (please specify below):	Yes 🗆	No \square			



Please provide clinical contact details of this	s presentation:				
Clinical contact	Clinical contacts during this Admission date – Discha presentation (dd/mm/yyyy)			rge date	
Visited Family doctor or pediatrician	Yes □ No □				
Visited ER	Yes □ No □				
Admission to hospital (for at least 1 night)	Yes 🗆 No 🗆				
ICU/CCU admission	Yes □ No □				
			·		
Section 5: Laboratory results / Toxic	ology / Investi	gations			
NOTE: Note: please follow provincia of all tests performed.	l guidelines/dir	ectives for labo	ratory testing	j. Please pr	ovide results
					Date sample
	R	esult	Not tested	Pending	collected (dd/mm/yyyy)
Laboratory marker					(12)
Highest ALT					
Highest AST					
Highest ALP					
Highest Bilirubin					
Highest INR					
PT					
Highest Fibrinogen					
Highest Ferritin					
D-dimer					
Lowest Albumin					
Peak LDH					
Peak GGT					
Peak CRP					
Peak WBC					
	Result			Date sample	
	Detected	Not detected	Not tested	Pending	collected (dd/mm/yyyy)
Infectious diseases					
CMV PCR in blood (indicate viral load if available)					
CMV Serology (IgG or IgM)					
EBV PCR in blood (indicate viral load if available)					



EBV Serology (IgG or IgM)

Section 5: Laboratory results / Toxicology / Investigations

NOTE: Note: please follow provincial guidelines/directives for laboratory testing. Please provide results of all tests performed.

	Result			Date sample	
	Detected	Not detected	Not tested	Pending	collected (dd/mm/yyyy)
Enterovirus PCR in blood (indicate viral load if available					
HSV – 1 PCR in blood (indicate viral load if available)					
HSV – 2 PCR in blood (indicate viral load if available)					
HHV-6					
HAV: PCR in blood if done, or stool, please specify:					
HAV: IgG					
HAV: IgM					
HBV (HBsAg)					
HBV DNA					
Hepatitis B antibody tests, please specify:					
HCV (Ab)					
HCV RNA					
HEV: IgM					
HEV: IgG					
HEV PCR in blood (or stool), please specify:					
Adenovirus – stool sample					
Adenovirus – respiratory sample					
Adenovirus – blood sample (indicate viral load)					
Adenovirus – other sample					
Adenovirus genotyping, indicate sample used:					
SARS-CoV-2 PCR – respiratory sample					
SARS-CoV-2 anti-spike and/or anti-N antibody					
RSV PCR – respiratory sample					
Influenza PCR – respiratory sample					
Enterovirus PCR – respiratory sample					
Varicella PCR in blood					
Parvovirus B19 IgM or IgG or PCR, please specify:					
HIV serology					



Section 5: Laboratory results / Toxicology / Investigations

NOTE: Note: please follow provincial guidelines/directives for laboratory testing. Please provide results of all tests performed.

	Result				Date sample collected
	Detected	Not detected	Not tested	Pending	(dd/mm/yyyy)
ASOT					
Throat swab for bacterial culture					
Stool for bacterial culture					
Stool PCR for norovirus and/or enterovirus (select those included if not all available)					
Other, please specify:					
Toxicology					
Heavy metal screen: Lead					
Heavy metal screen: Arsenic					
Heavy metal screen: Mercury					
Drug screen: Peak acetaminophen concentration					
Urine toxicology, please provide details of any positive tox results:					
Investigations	Performed	If yes, plea	se summarise fi	ndings:	Date of test
Radiology:					
X-rays	Yes □ No □				
Abdominal ultrasound scan	Yes □ No □				
CT scan	Yes □ No □				
Liver biopsy (summarise histopathology report, including whether damage starting at portal tracts or diffuse)	Yes □ No □				
List immunohistochemistry stains performed (adenovirus/CMV/EBV etc)	Yes □ No □				

Section 6: Case medical and health history						
Did the case have COVID-19? Yes □	Suspected □ Unkr	nown 🗆 No 🗆				
If yes, was it confirmed by a test? Y	′es □ [PCR □; Rapid	test □] No □				
Date of COVID-19 onset (most rece	ent episode) <i>(dd/mm/</i>)	· /yyy):				
Please summarize any other previous illne	esses requiring treatm	nent/care in the 5 m	onths prior to diagnos	sis:		
Illness type (e.g. gastrointestinal illness,	Hospitalisation	Date of onset/	Primary	Over the counter		
injury)	required (yes/no)	days to	Symptoms	or prescribed		
		resolution		medication taken		
Please describe any other medication the	case has been					
prescribed in the 5 months prior to diagno						
Does the case have any underlying medic	cal condition?	Yes □ No □				
Including liver related/metabolic/autoimmu	une/ischaemic					
If yes, details: (diagnosis, date of diagnos	is, medication)					
Is the case immunosuppressed?		Yes □ No □				
If yes, details: (condition (include if primary, secondary,						
medication related), date of diagnosis, medication)						
Does or has the case take(n) any supplements or medicines		Yes □ No □				
acquired, over the counter, purchased over the internet or						
accessed by any other methods? (Including						
alternative medicines, vitamins or other su						
specifically, prompt acetaminophen/ anti-i	nflammatory drugs					
(e.g. aspirin, ibuprofen)/anticonvulsants in						
to diagnosis?						
If yes, details: (product, dose and frequen	cy, where					
purchased)						
Has the patient received any vaccine in the 5 months prior to		Yes □ No □				
diagnosis?						
If yes, details: (type, date of administration)						
Has the patient received a COVID-19 vaccine?		Yes □ No □				
		Date:				
Does the patient have autoimmune hepatitis?		If yes, details:				
Yes □ No □ Unknown □						
Does the patient have HLH (Hemophagod	If yes, details:					
Lymphohistiocytosis)? Yes \Box No \Box						



Section 7: Travel History	
In the 5 months prior to diagnosis of acute hepatitis, has the case travelled outside of Canada?	Yes ☐ No ☐ If yes, please specify location and date of travel:
Section 8: Any other information	
Comments:	

END OF QUESTIONNAIRE